20.500.12556/RUL-171701 Terapevtski potencial psilocibina pri zdravljenju depresije The therapeutic potential of psilocybin in the treatment of depression Diplomska naloga obravnava terapevtski potencial psilocibina pri zdravljenju depresije, zlasti pri bolnikih, ki se ne odzivajo na konvencionalna zdravljenja. Psilocibin, psihoaktivna spojina iz gliv rodu Psilocybe, se po zaužitju presnovi v psilocin, ki kot agonist serotoninskih receptorjev tipa 5-HT2A spodbuja nevroplastičnost. Klinične študije so pokazale, da enkratna do dvakratna aplikacija psilocibina, ob podpori psihoterapije, povzroči hitro in trajno zmanjšanje depresivnih simptomov. Študija, v kateri so udeleženci prejeli 25 mg psilocibina, je pri bolnikih z depresijo povzročila klinično pomembno zmanjšanje rezultatov na lestvici MADRS (Montgomery–Åsberg Depression Rating Scale). V študiji z 12-mesečnim spremljanjem udeležencev po zaužitju psilocibina je bilo izboljšanje vzdržano brez dodatne farmakoterapije. Dodatno je bila intenzivnost mistične izkušnje, zlasti komponenta oceanske brezmejnosti (OBN), statistično povezana z večjo stopnjo izboljšanja depresivnih simptomov. Psilocibin ima nizko toksičnost, hiter razvoj tolerance in nizek zasvojitveni potencial. Najpogostejši neželeni učinki so bili glavobol, slabost, anksioznost, omotica in zvišan krvni tlak, a so bili prehodni. V ustreznem terapevtskem okviru psilocibin predstavlja varno in učinkovito alternativo antidepresivom, zlasti pri bolnikih z depresijo, odporno na zdravljenje. Potrebne pa so nadaljnje študije za določitev dolgoročne varnosti, standardizacije odmerjanja ter regulativnega okvira. The thesis examines the therapeutic potential of psilocybin in the treatment of depression, particularly in patients who do not respond to conventional therapies. Psilocybin, a psychoactive compound found in fungi of the genus Psilocybe, is metabolized after ingestion into psilocin, which, as an agonist of 5-HT2A serotonin receptors, promotes neuroplasticity. Clinical studies have shown that one or two administrations of psilocybin, combined with psychotherapeutic support, lead to a rapid and lasting reduction in depressive symptoms. In a study where participants received 25 mg of psilocybin, patients with depression experienced a clinically significant reduction in scores on the Montgomery–Åsberg Depression Rating Scale (MADRS). In a study with 12-month follow-up of participants after psilocybin administration, the improvement was maintained without additional pharmacotherapy. Furthermore, the intensity of the mystical experience, particularly the Oceanic Boundlessness (OBN) component, was statistically associated with a greater degree of improvement in depressive symptoms. Psilocybin has low toxicity, rapid tolerance development, and low addictive potential. The most common adverse effects were headache, nausea, anxiety, dizziness, and elevated blood pressure, but these were transient. Within an appropriate therapeutic framework, psilocybin represents a safe and effective alternative to antidepressants, especially for patients with treatment-resistant depression. However, further studies are required to determine its long-term safety, dosing standardization, and regulatory framework. psilocibin psilocin depresija terapevtski potencial psilocybin psilocin depression therapeutic potential true false false Slovenski jezik Angleški jezik Diplomsko delo/naloga 2025-08-31 07:15:33 2025-08-31 07:15:44 2025-09-15 03:51:11 0000-00-00 00:00:00 2025 0 0 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 261879 247199491 50774.pdf 50774.pdf 1 3FE88FDEF6CB6C9897441F0F2221B819 081a123764b3af92ccef55e13be918b3bcf46dd4b489116735ed5383bd355a78 67aadbda-8629-11f0-9328-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=215083 Biotehniška fakulteta 0 0 0